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Background. This study estimated the number of daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
doses required to achieve and maintain (after discontinuation) intracellular drug concentrations that protect against
human immunodeficiency virus (HIV) infection for men who have sex with men (MSM).
Methods. Tenofovir diphosphate (TFV-DP) concentrations in peripheral blood mononuclear cells (PBMCs)
and rectal mononuclear cells from an intensive pharmacokinetic study (“Cell-PrEP” [preexposure prophylaxis])
of 30 days of daily TDF/FTC followed by 30 days off drug were evaluated. A regression formula for HIV risk reduc-
tion derived from PBMCs collected in the preexposure prophylaxis initiative study was used to calculate inferred risk
reduction. The time required to reach steady state for TFV-DP in rectal mononuclear cells was also determined.
Results. Twenty-one HIV-uninfected adults participated in Cell-PrEP. The inferred HIV risk reduction, based
on PBMC TFV-DP concentration, reached 99% (95% confidence interval [CI], 69%–100%) after 5 daily doses, and
remained >90% for 7 days after stopping drug from steady-state conditions. The proportion of participants reaching
the 90% effective concentration (EC90) was 77% after 5 doses and 89% after 7 doses. The percentage of steady state for
natural log [TFV-DP] in rectal mononuclear cells was 88% (95% CI, 66%–94%) after 5 doses and 94% (95% CI,
78%–98%) after 7 doses.
Conclusions. High PrEP activity for MSM was achieved by approximately 1 week of daily dosing. Although ef-
fective intracellular drug concentrations persist for several days after stopping PrEP, a reasonable recommendation is
to continue PrEP dosing for 4 weeks after the last potential HIV exposure, similar to recommendations for postex-
posure prophylaxis.
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New human immunodeficiency virus (HIV) infections
have increased among young minority men who have
sex with men (MSM) in recent years [1]. Preexposure
prophylaxis (PrEP) with daily tenofovir disoproxil
fumarate/emtricitabine (TDF/FTC) provides an im-
portant tool for preventing HIV infection in MSM as
well as heterosexual adults at risk for exposure to HIV
[2–7]. Several guidelines for PrEP have been published;
however, there is a lack of recommendations regarding
how to start and stop PrEP relative to potential HIV expo-
sures. Therefore, studies are needed that estimate the onset
and duration of high PrEP activity (eg, >90% efficacy).
Knowledge of the pharmacokinetic/pharmacody-
namic (PK/PD) profile for PrEP is required to estimate
the onset and duration of PrEP activity. Such informa-
tion was generated using data from the preexposure
prophylaxis initiative (iPrEx) trial, a large, randomized
placebo controlled study that enrolled 2499 transgender
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women and MSM [8, 9]. A post hoc regression analysis iden-
tified a continuous relationship between HIV risk reduction
(relative to placebo) and intracellular tenofovir diphosphate
(TFV-DP) concentration, the pharmacologically active moiety
for tenofovir, in viable cryopreserved peripheral blood mononu-
clear cells (vPBMCs). A benchmark in the continuous relation-
ship was that a TFV-DP concentration of 16 (95% confidence
interval [CI], 3–28) fmol/106 cells was associated with a 90% re-
duction in HIV acquisition [10]; this was referred to as the EC90
(ie, the 90% effective concentration). The objective of the present
study was to apply the regression formula derived from iPrEx to
PBMC TFV-DP concentrations from an intensive pharmacoki-
netic study in HIV-uninfected persons (Cell-PrEP) to estimate
HIV risk reduction per TDF/FTC dose.
METHODS
Intensive Pharmacokinetic Study Design
Cell-PrEP was a prospective, observational, pharmacokinetic
study in HIV-uninfected adult male and female volunteers
aged 18–55 years, conducted at the University of Colorado Den-
ver, Anschutz Medical Campus (ClinicalTrials.gov identifier
NCT01040091). The study was approved by the institutional re-
view board and participants provided written informed consent
prior to participating. Subjects received daily TDF 300 mg/FTC
200 mg (as Truvada) for 30 days, followed by 30 days off drug;
the total study duration was 60 days.
PBMCs were collected on days 1, 3, 7, 20, 30, 35, 45, and 60.
On days 1 and 30, blood was collected at 1-, 2-, 4-, 8-, and 24-
hour intervals postdose; on days 3, 7, and 20, blood was collect-
ed predose and at 2 and 8 hours postdose. Subjects were asked
to fast overnight, beginning at 10 PM, prior to their dosing visits
(days 1–30). Rectal biopsy samples were collected once for each
subject at 2 hours postdose at one of their dosing visits. These
collections were staggered such that 4 participants had the rectal
biopsy for each of the 5 dosing visits (days 1, 3, 7, 20, and 30).
For the washout phase, blood was collected on days 35, 45, and
60. A window of several days was allowed around all scheduled
visits. Adherence was determined by pill count, self-report, and
a dosing calendar on which participants recorded dosing times.
Freshly Lysed PBMC Processing
PBMCs were harvested from cell preparation tubes with standard
laboratory procedures. Red blood cells (RBCs) were lysed with
RBC lysis buffer followed by rinsing and automated cell counting
(Countess, Invitrogen). Cells were lysed in 500 µL methanol:
water (MeOH:H2O) and stored at –80°C until analysis.
Viable Cryopreserved PBMC Processing
At the day 7 visit, a vPBMC sample was collected along with the
freshly lysed PBMC sample (as described above) at the predose
time point. The vPBMC sample was processed using a freezing
solution of Roswell Park Memorial Institute medium (RPMI),
fetal bovine serum, and dimethyl sulfoxide, and the viable
cells were stored at –80°C until processing for the assay. Just
prior to assaying, the frozen PBMC samples were thawed and
processed with the same procedures that were described previ-
ously for the iPrEx analysis [8, 10].
Rectal Mononuclear Cell Isolation
Approximately 20 pinches of rectal tissue were collected by a
gastroenterologist during sigmoidoscopy from 4 to 12 inches
into the rectum using a 3-mm forceps. Biopsies were placed
into 30 mL of phosphate-buffered saline and washed with com-
plete RPMI, followed by 2–3 digestions with Collagenase solu-
tion at 37°C for 30 minutes, with gentle agitation. The cell
suspension was collected by straining the digested solution
through a cell strainer. After RBC lysis, the remaining mononu-
clear cells were washed, counted, assessed for viability, lysed in
500 µL of MeOH:H2O, and stored at −80°C until analysis.
Drug Assay
TFV-DP and emtricitabine-triphosphate (FTC-TP) concentra-
tions in lysed cellular matrices were assayed with a validated liq-
uid chromatography–tandem mass spectrometry method, as
described previously [11]. The lower limit of quantification
(LOQ) was 2.5 fmol/sample for TFV-DP and 0.1 pmol/sample
for FTC-TP. This was the same analytical procedure used pre-
viously to assay iPrEx samples [8].
Pharmacokinetic Analysis
All TFV-DP and FTC-TP concentrations in PBMCs from all
visits in all participants were used for the pharmacokinetic
model. The pharmacokinetic concentration–time profiles for
each individual were characterized using a 1-compartment
constant drug input model with Phoenix WinNonlin. Rectal
mononuclear cell concentrations were characterized with the
same model using GraphPad Prism version 6.00 (GraphPad
Software, La Jolla, California) with least squares regression,
but using a naive-pooled approach.
Data Analysis
Freshly lysed PBMC TFV-DP concentrations from Cell-PrEP
were converted to vPBMC values for use in the iPrEx regression
formula [10], because the iPrEx regression formula was gener-
ated using TFV-DP from vPBMC, and the samples from Cell-
PrEP were freshly lysed PBMCs. Multiple imputation was used
for inferring the TFV-DP values in vPBMCs. The multiple im-
putation used data from 65 paired viable-fresh values, including
some from HIV-infected individuals. Each predicted viable
cryopreserved TFV-DP value was the result of 20 imputations
that accounted for variability. Sensitivity analyses were conduct-
ed using multiple imputation with the following reduced
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datasets for viable-fresh values: removing values from viable
cryopreserved samples in short-term storage (≤3 months), re-
moving values from HIV-infected persons, removing values
from women in Cell-PrEP, and removing values from those in
Cell-PrEP with known missed doses. Finally, the raw TFV-DP
concentrations in vPBMC from the day 7 visit of Cell-PrEP were
directly applied to the iPrEx regression formula (n = 20). These
TFV-DP results corresponded to the predose concentration on
days 5, 6, or 7, depending on when the participant came in dur-
ing their day 7 visit window. This included 1 vPBMC result that
showed no signal for TFV-DP (or FTC-TP) despite a high value
in the freshly lysed sample (greater than the 75th percentile of
freshly lysed values). A TFV-DP value of “0” was included for
this sample.
The mean log vPBMC values were modeled using a linear
mixed effects model with a cubic spline fit to days since starting
daily TDF/FTC. Three approaches were used to estimate the
onset and duration of PrEP activity. First, the inferred HIV
risk reduction was calculated using estimated TFV-DP concen-
trations (in vPBMCs) from Cell-PrEP and analyzed with a pre-
viously described regression equation from iPrEx [10], for each
dose of daily TDF/FTC, as well as each day after TDF/FTC dos-
ing was stopped. Second, the proportion of Cell-PrEP individ-
uals with TFV-DP concentrations greater than or equal to the
iPrEx EC90 (16 fmol/10
6 vPBMCs) was determined over the
same time frame. Finally, to evaluate corresponding drug con-
centrations at an important site of drug action in MSM, the time
that TFV-DP concentrations reached steady state in rectal
mononuclear cells was determined.
RESULTS
Subject Characteristics
Twenty-one HIV-uninfected men and women were enrolled in
Cell-PrEP, and 19 completed all study visits. Of the 2 partici-
pants who did not complete all study visits, 1 had grade II
low phosphorus and was removed from the study per protocol,
while the other participant chose to withdraw for personal rea-
sons. Nineteen rectal samples were collected and analyzed from
19 participants, and 410 PBMC samples were analyzed from 21
participants. The demographics of the study participants are
shown in Table 1. A total of 5 missed doses (out of 584
doses) were reported by participants in the study, supported
by pill counts, indicating an overall adherence of 99%.
Inferred HIV Risk Reduction
The inferred HIV risk reduction based on PBMC TFV-DP con-
centration was 77% (95% CI, 40%–93%) after 1 dose, 96% (95%
CI, 60%–100%) after 3 doses, 99% (95% CI, 69%–100%) after 5
doses, and 99% (95% CI, 70%–100%) after 7 doses (Figure 1).
The inferred risk reduction did not reach 100% during the
study. The corresponding inferred risk reduction from the sen-
sitivity analyses ranged from 75% to 81% after 1 dose, 95% to
97% after 3 doses, and 98% to 99% after 5 and 7 doses. Analysis
of the raw TFV-DP concentrations from the day 7 visit (pre-
dose from doses 5, 6, or 7), with and without the sample with
no drug detection, revealed a 92% and 96% risk reduction, re-
spectively. After dosing was discontinued at day 30, the inferred
risk reduction remained >90% for 7 days. In sensitivity analyses,
after stopping drug for 7 days from day 30, the risk reduction
ranged from 90% to 94%.
Proportion Above the iPrEx EC90
The proportion of PBMC TFV-DP concentrations that reached
the iPrEx EC90 was 30% after 1 dose, 55% after 3 doses, 77%
after 5 doses, 89% after 7 doses, and 98% after the 13th dose
(Figure 1). The proportion reaching the iPrEx EC90 did not
reach or exceed 99% during the study. The corresponding val-
ues from the sensitivity analyses ranged from 26% to 41% after 1
dose, 53% to 67% after 3 doses, 78% to 85% after 5 doses, 91% to
95% after 7 doses, and 99% after the 13th dose. Analysis of the
raw TFV-DP concentrations from the day 7 visit (predose from
doses 5, 6, or 7), with and without the sample with no drug de-
tection, revealed 85% and 89% above the iPrEx EC90, respective-
ly. After stopping drug, 80% of TFV-DP concentrations
remained above the iPrEx EC90 for 2 days, decreasing to 48%
at 7 days postdrug discontinuation. In sensitivity analyses, the
proportion of concentrations above the EC90 ranged from
86% to 91% at 2 days after stopping drug, and 48% to 63% at
7 days after stopping drug.
Rectal Mononuclear Cell Concentrations
Seventeen of the 19 rectal samples had quantifiable TFV-DP
concentrations, whereas 2 samples had concentrations below
Table 1. Overall Demographics and Baseline Characteristics
(N = 21)
Characteristic No. (%) or Median (Range)






African American 10 (47.6)
Hispanic 1 (4.8)
Weight, kg 81.1 (56.5–124.4)
BMI, kg/m2 27.2 (20.8–37.7)
eGFR, mL/min/1.73 m2 93.3 (67.8–128.6)
Abbreviations: BMI, body mass index; eGFR, estimated glomerular filtration
rate.
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the LOQ, both from the first-dose visit. One of the 19 FTC-TP
concentrations was below the LOQ, from the day 3 visit. A value
midway between 0 and the lower LOQwas used for these concen-
trations in all calculations. TFV-DP concentrations were natural
log (ln) transformed prior to fitting the pharmacokinetic model
(Figure 2). The half-life of rectal mononuclear cell TFV-DP (ln)
was 1.7 (95% CI, 1.2–3.2) days and the steady-state concentration
(ln) was 7.6 (95% CI, 6.8–8.4) fmol/106cells, corresponding to
1961 (95% CI, 854–4501) fmol/106cells after back-transforma-
tion. The half-life based on this model predicted that 71%
(95% CI, 48%–82%) of steady-state was reached after 3 doses,
88% (95% CI, 66%–94%) after 5 doses, and 94% (95% CI,
78%–98%) after 7 doses. The steady-state FTC-TP concentration
in rectal mononuclear cells was 0.96 (95% CI, 0.53–1.4) pmol/
106cells, but the half-life could not be accurately estimated (1.5
[95% CI, 0.5–∞] days) (Figure 2).
PBMC Pharmacokinetics
The 2 participants who withdrew early were not included in the
pharmacokinetic modeling for PBMCs, but their data were in-
cluded in the inferred risk reduction analyses described above.
Using the concentrations from dosing visits, the mean TFV-DP
steady-state concentration was 103 fmol/106cells (coefficient of
variation [CV], 32%) and the mean half-life was 3.5 days (CV,
31%) in the 19 participants who completed all study visits (Fig-
ure 3). Eighteen percent of steady-state was achieved after 1
dose, 45% after 3 doses, 63% after 5 doses, 75% after 7 doses,
and >90% after 12 doses. The mean FTC-TP steady-state con-
centration was 6 pmol/106cells (CV, 22%) and the mean half-
life was 33 hours (CV, 42%) (Figure 3). Forty percent of steady
state was achieved after 1 dose, 78% after 3 doses, 92% after 5
doses, and 97% after 7 doses. There were no differences between
men and women in steady-state TFV-DP (P = .46) or FTC-TP
(P = .69) concentrations.
DISCUSSION
This study evaluated pharmacokinetic data from daily dosing in
Cell-PrEP with a pharmacodynamic model for HIV risk reduc-
tion from iPrEx, and calculated an inferred HIV risk reduction
that reached 99% by 5 days of daily dosing. This 99% value pro-
vides an average estimate based on the set of TFV-DP concen-
trations from Cell-PrEP participants for each daily dose,
suggesting that most concentrations conferred nearly 100% ef-
ficacy from the fifth dose onward. Sensitivity analyses, including
one in which data from female participants were excluded,
showed consistent results.
A second, more conservative approach, showed that the ma-
jority of Cell-PrEP participants exceeded the iPrEx EC90 by the
fifth or seventh doses, approximately 80% and 90%, respective-
ly, and that the maximum proportion was achieved by the 13th
dose (98%). Reaching the highest proportion by the 13th dose
was consistent with the pharmacokinetic profile of TFV-DP in
PBMCs, which demonstrated that >90% steady state was
achieved after approximately 12 doses (Figure 3). FTC-TP in
PBMCs achieved steady state more rapidly—92% after 5 doses
and 97% after 7 doses.
A third approach focused on TFV-DP (ln transformed) at an
important site of action in MSM, in rectal mononuclear cells,
showing that 88% and 94% of steady state were achieved after
Figure 1. Inferred human immunodeficiency virus (HIV) risk reduction and proportion ≥90% effective concentration (EC90). A, Study day is depicted on the
x-axis; inferred HIV risk reduction is depicted on the y-axis. The solid line represents the point estimate for reduced risk for HIV infection; the dashed lines
represent the 95% confidence interval (CI). B, Proportion of participants with tenofovir diphosphate (TFV-DP) concentrations in viable cryopreserved periph-
eral blood mononuclear cells (vPBMCs) at or above the preexposure prophylaxis initiative (iPrEx) (16 fmol/106cells) is depicted on the y-axis. The solid line
represents the proportion of participants with TFV-DP concentrations at or above the iPrEx EC90 by day in the study.
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5 and 7 doses, respectively (Figure 2). FTC-TP concentrations
in rectal mononuclear cells also appeared to reach steady state
by this time.
Taken together, a high level of PrEP activity was achieved by
5–7 doses, indicating that, for optimal benefit, PrEP should be
started approximately 1 week before it is needed. It is important
to note that this analysis was based on data in MSM (iPrEx), so
these results should not be extrapolated to women, heterosexual
men, or other routes of transmission. Understanding and apply-
ing PK/PD analyses for PrEP in women, and populations other
than MSM, is an urgent research priority.
Other studies also support approximately 1 week of lead-in
time for starting PrEP in MSM. The HIV Prevention Trials Net-
work (HPTN) 066 study, which used directly observed dosing
for 5 weeks to characterize TFV-DP and FTC-TP in PBMCs
among 45 HIV-uninfected men and women, showed that steady
state was achieved by 7 days for both TFV-DP and FTC-TP [12].
An advantage of HPTN 066 compared with Cell-PrEP was the
directly observed dosing design. Reaching steady state by 7 days
indicates that inferred HIV risk reduction and proportion above
the iPrEx EC90 would plateau by day 7. Another study with con-
sistent results was the iPrEx Open Label Extension, which
showed that no HIV infections were observed in MSM when
PrEP dosing was estimated to be ≥4 doses per week (HIV
risk reduction, 100% [95% CI, 84%–100%]) [13], corresponding
to greater than four-sevenths (57%) of steady-state concentra-
tions. This level of steady state (57%) would be achieved in
the present study after 4 doses using TFV-DP kinetics in
PBMCs and 2 doses in rectal mononuclear cells. Finally, the
Ipergay study evaluated placebo vs 2 TDF/FTC tablets before
anticipated sex followed by 1 tablet 24 and 48 hours after sex
among MSM [14]. An unblinded analysis by the data safety
monitoring board showed that a significant reduction in HIV
incidence (magnitude not reported) was observed in the TDF/
FTC vs placebo group. Together these observations support
high PrEP activity by approximately 1 week for MSM [15].
The considerations for how to safely stop PrEP after the last
potential HIV exposure are not as straightforward. The present
study found that high PrEP activity was evident for several days
after dosing was stopped. The inferred risk reduction exceeded
90% for 7 days, and 80% of participants remained above the
iPrEx EC90 for 2 days after stopping PrEP. However, an impor-
tant consideration for discontinuing PrEP is how long it takes
for HIV to be completely cleared from the body following the
last potential exposure. There appears to be little consensus on
this issue given that several variables may affect the HIV clear-
ance process, such as whether HIV is endocytosed into Langer-
hans cells (where it may persist for days), and/or adhered to
follicular dendritic cells, and/or whether early cycles of HIV
replication occur [16, 17]. As early stages of viral replication
occur, longer times are required to completely clear the virus,
and the chance for establishing latent infection increases. This
was demonstrated in early postexposure prophylaxis (PEP)
studies in animals that showed 50% vs 100% efficacy for 10
days vs 28 days of tenofovir dosing when started 24 hours
after intravenous simian immunodeficiency virus exposure
[16].These considerations underlie the current PEP recommen-
dations to treat potential HIV exposures for 28 days [18].
PrEP differs from PEP in that early replication is presumably
blocked by PrEP, as long as PrEP activity is high, perhaps allow-
ing for a faster HIV clearance rate in the setting of PrEP. Similar
efficacy was found in animal studies that compared continued
PrEP dosing for 28 days after the last viral inoculation vs
discontinued dosing after the last viral inoculation [19]. These
considerations suggest that shorter durations of dosing might
be adequate for PrEP following the last potential HIV expo-
sure, but not enough information is available to make specific
recommendations. This should be an area of future research.
Until then, a conservative recommendation would be to continue
dosing for 4 weeks after the last potential HIV exposure.
Figure 2. Tenofovir diphosphate (TFV-DP) and emtricitabine-triphosphate
(FTC-TP) in rectal mononuclear cells. A, Concentrations of TFV-DP in rectal
mononuclear cells were first natural log (ln) transformed and then fit using
a nonlinear 1-phase exponential association [Ct = Css × (1-e−K×t)], where Ct
is the (ln) concentration at time t, Css is the fitted (ln) steady-state drug
concentration, and K is the fitted first-order elimination rate constant. B,
FTC-TP concentrations (not ln transformed) in rectal mononuclear cells
were fit with the same nonlinear 1-phase exponential association.
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The strengths of this study include the several lines of evi-
dence used to estimate PrEP efficacy for each daily dose, includ-
ing use of a PK/PD model from iPrEx to analyze drug
concentrations from an intensive pharmacokinetic study, Cell-
PrEP, with all drug concentrations processed and assayed with
the same laboratory procedures; analysis of drug accumulation
at an important site of action for MSM; and the consistency of
the findings from this study with other studies. The main lim-
itations include that the onset and duration of action could not
be studied directly in vivo, and that these results were based
upon studies in MSM, so the findings cannot be extrapolated
to other modes of transmission such as vaginal, penile (hetero-
sexual), or parenteral. Additionally, other HIV transmission
characteristics may be important to the PK/PD profile, but
were not considered here, such as the viral inoculum size
[20]. Last, adherence in Cell-PrEP was monitored using self-re-
port and pill count, which may not have accurately reflected
true dose-taking behavior among participants [21].
In summary, this study indicates that approximately 1 week
of daily PrEP is expected to confer high PrEP activity for MSM.
Although a high level of protection may persist for several days
after stopping PrEP from steady state, 4 weeks of continued
PrEP dosing is reasonable relative to the last potential HIV
exposure.
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